Skip to main content

Table 1 Clinical characteristics of breast cancer patients

From: GSTP1 c.313A > G mutation is an independent risk factor for neutropenia hematotoxicity induced by anthracycline-/paclitaxel-based chemotherapy in breast cancer patients

  Number (mean ± SD) Percentage (%)
Age (year)
 <35 16 (31.00 ± 2.68) 11.3
 35–50 60 (43.20 ± 4.70) 42.2
 >50 66 (57.47 ± 5.19) 46.5
Menopause
 No 83 58.5
 Yes 59 41.5
T-stage
 T0–T2 61 43.0
 T3–T4 81 57.0
N-stage
 N0–N1 43 30.3
 N2–N3 99 69.7
Clinical stage
 I–III 108 76.1
 IV 34 23.9
Molecular subtypes
 Luminal A 10 7.0
 Luminal B 77 54.2
 HER2 +  33 23.2
 TNBC 22 15.5
Chemotherapy regimena
 TEC (docetaxel 75 mg/m2, epirubicin 75 mg/m2) 114 80.3
 EC-T/EC-TH (docetaxel 90 mg/m2, epirubicin 90 mg/m2) 23 16.2
 TCbH (taxane 175 mg/m2) 3 2.1
 TCb (taxane 175 mg/m2) 1 0.7
 EC (epirubicin 90 mg/m2) 1 0.7
  1. ER Estrogen receptor, PR Progesterone receptor; TNBC Triple-negative breast cancer
  2. aOnly the doses of anthracycline and paclitaxel in different regimens were shown